MedPath

BeyondSpring

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$80.1M
Website

BeyondSpring's Plinabulin Shows Promising Survival Benefits in Lung Cancer and Strategic Advances in Protein Degradation

BeyondSpring's Plinabulin demonstrated statistically significant survival benefits in second and third-line non-small cell lung cancer (EGFR wild-type) patients, with results published in The Lancet Respiratory Medicine.

© Copyright 2025. All Rights Reserved by MedPath